316 related articles for article (PubMed ID: 35290663)
21. Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14.
Murch SH
Med Hypotheses; 2020 Nov; 144():110168. PubMed ID: 33254494
[TBL] [Abstract][Full Text] [Related]
22. mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2.
Yu Z; Maoui M; Wu L; Banville D; Shen S
Biochem J; 2001 Feb; 353(Pt 3):483-92. PubMed ID: 11171044
[TBL] [Abstract][Full Text] [Related]
23. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus.
Ali SR; Fong JJ; Carlin AF; Busch TD; Linden R; Angata T; Areschoug T; Parast M; Varki N; Murray J; Nizet V; Varki A
J Exp Med; 2014 Jun; 211(6):1231-42. PubMed ID: 24799499
[TBL] [Abstract][Full Text] [Related]
24. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
25. Negative regulation of leucocyte functions by CD33-related siglecs.
Avril T; Attrill H; Zhang J; Raper A; Crocker PR
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1024-7. PubMed ID: 17073742
[TBL] [Abstract][Full Text] [Related]
26. Siglec-6 Signaling Uses Src Kinase Tyrosine Phosphorylation and SHP-2 Recruitment.
Stefanski AL; Renecle MD; Kramer A; Sehgal S; Narasimhan P; Rumer KK; Winn VD
Cells; 2022 Oct; 11(21):. PubMed ID: 36359823
[TBL] [Abstract][Full Text] [Related]
27. Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia.
Angata T; Kerr SC; Greaves DR; Varki NM; Crocker PR; Varki A
J Biol Chem; 2002 Jul; 277(27):24466-74. PubMed ID: 11986327
[TBL] [Abstract][Full Text] [Related]
28. Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers.
Lin CH; Yeh YC; Yang KD
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):5-24. PubMed ID: 31882261
[TBL] [Abstract][Full Text] [Related]
29. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
30. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.
Brinkman-Van der Linden EC; Varki A
J Biol Chem; 2000 Mar; 275(12):8625-32. PubMed ID: 10722702
[TBL] [Abstract][Full Text] [Related]
31. Human Siglec-5 inhibitory receptor and immunoglobulin A (IgA) have separate binding sites in streptococcal beta protein.
Nordström T; Movert E; Olin AI; Ali SR; Nizet V; Varki A; Areschoug T
J Biol Chem; 2011 Sep; 286(39):33981-91. PubMed ID: 21795693
[TBL] [Abstract][Full Text] [Related]
32. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.
Cornish AL; Freeman S; Forbes G; Ni J; Zhang M; Cepeda M; Gentz R; Augustus M; Carter KC; Crocker PR
Blood; 1998 Sep; 92(6):2123-32. PubMed ID: 9731071
[TBL] [Abstract][Full Text] [Related]
33. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E.
Redelinghuys P; Antonopoulos A; Liu Y; Campanero-Rhodes MA; McKenzie E; Haslam SM; Dell A; Feizi T; Crocker PR
J Biol Chem; 2011 Oct; 286(40):34522-32. PubMed ID: 21835922
[TBL] [Abstract][Full Text] [Related]
34. Ganglioside binding pattern of CD33-related siglecs.
Rapoport E; Mikhalyov I; Zhang J; Crocker P; Bovin N
Bioorg Med Chem Lett; 2003 Feb; 13(4):675-8. PubMed ID: 12639556
[TBL] [Abstract][Full Text] [Related]
35. Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides.
Rapoport EM; Pazynina GV; Sablina MA; Crocker PR; Bovin NV
Biochemistry (Mosc); 2006 May; 71(5):496-504. PubMed ID: 16732727
[TBL] [Abstract][Full Text] [Related]
36. Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.
Islam M; Arlian BM; Pfrengle F; Duan S; Smith SA; Paulson JC
J Am Chem Soc; 2022 Jun; 144(21):9302-9311. PubMed ID: 35593593
[TBL] [Abstract][Full Text] [Related]
37. Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation.
Büll C; Collado-Camps E; Kers-Rebel ED; Heise T; Søndergaard JN; den Brok MH; Schulte BM; Boltje TJ; Adema GJ
Immunol Cell Biol; 2017 Apr; 95(4):408-415. PubMed ID: 27874015
[TBL] [Abstract][Full Text] [Related]
38. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
39. Basic and clinical immunology of Siglecs.
von Gunten S; Bochner BS
Ann N Y Acad Sci; 2008 Nov; 1143():61-82. PubMed ID: 19076345
[TBL] [Abstract][Full Text] [Related]
40. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake.
Jones C; Virji M; Crocker PR
Mol Microbiol; 2003 Sep; 49(5):1213-25. PubMed ID: 12940982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
